Literature DB >> 28024081

Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia.

D L Ouellet1,2, K Cherif1,2, J Rousseau1,2, J P Tremblay1,2.   

Abstract

The Friedreich ataxia is a monogenic disease due to a hyperexpanded GAA triplet located within the first intron of the frataxin gene that causes transcriptional issues. The resulting frataxin protein deficiency leads to a Fe-S cluster biosynthesis dysfunction in the mitochondria and to oxidative stress and cell death. Here we use the CRISPR-Cas9 system to remove the mutated GAA expansion and restore the frataxin gene transcriptional activity and protein level. Both YG8R and YG8sR mouse models and cell lines derived from these mice were used to CRISPR-edited successfully the GAA expansion in vitro and in vivo. Nevertheless, our results suggest the YG8sR as a better and more suitable model for the study of the CRISPR-Cas9 edition of the mutated frataxin gene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28024081     DOI: 10.1038/gt.2016.89

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  50 in total

Review 1.  Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy.

Authors:  David R Lynch; Jennifer M Farmer; Laura J Balcer; Robert B Wilson
Journal:  Arch Neurol       Date:  2002-05

Review 2.  Iron and Friedreich ataxia.

Authors:  M Pandolfo
Journal:  J Neural Transm Suppl       Date:  2006

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

Review 4.  Molecular pathogenesis of Friedreich ataxia.

Authors:  M Pandolfo
Journal:  Arch Neurol       Date:  1999-10

Review 5.  CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.

Authors:  M Sachdeva; N Sachdeva; M Pal; N Gupta; I A Khan; M Majumdar; A Tiwari
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

Review 6.  Friedreich ataxia: the clinical picture.

Authors:  Massimo Pandolfo
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

7.  FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia.

Authors:  Yogesh K Chutake; Whitney N Costello; Christina C Lam; Aniruddha C Parikh; Tamara T Hughes; Michael G Michalopulos; Mark A Pook; Sanjay I Bidichandani
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

8.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

9.  Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells.

Authors:  Susan M Byrne; Luis Ortiz; Prashant Mali; John Aach; George M Church
Journal:  Nucleic Acids Res       Date:  2014-11-20       Impact factor: 16.971

10.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.

Authors:  D G Courtney; J E Moore; S D Atkinson; E Maurizi; E H A Allen; D M L Pedrioli; W H I McLean; M A Nesbit; C B T Moore
Journal:  Gene Ther       Date:  2015-08-20       Impact factor: 5.250

View more
  19 in total

Review 1.  CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Authors:  Erin R Burnight; Joseph C Giacalone; Jessica A Cooke; Jessica R Thompson; Laura R Bohrer; Kathleen R Chirco; Arlene V Drack; John H Fingert; Kristan S Worthington; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2018-03-22       Impact factor: 21.198

Review 2.  Close encounters: Moving along bumps, breaks, and bubbles on expanded trinucleotide tracts.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  DNA Repair (Amst)       Date:  2017-06-09

Review 3.  On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability.

Authors:  Alexandra N Khristich; Sergei M Mirkin
Journal:  J Biol Chem       Date:  2020-02-14       Impact factor: 5.157

Review 4.  Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.

Authors:  Sudhanshu P Raikwar; Nidhi S Kikkeri; Ragha Sakuru; Daniyal Saeed; Haris Zahoor; Keerthivaas Premkumar; Shireen Mentor; Ramasamy Thangavel; Iuliia Dubova; Mohammad Ejaz Ahmed; Govindhasamy P Selvakumar; Duraisamy Kempuraj; Smita Zaheer; Shankar S Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

5.  CRISPR-SCReT (CRISPR-Stop Codon Read Through) method to control Cas9 expression for gene editing.

Authors:  Pouiré Yaméogo; Benjamin L Duchêne; Nathalie Majeau; Jacques P Tremblay
Journal:  Gene Ther       Date:  2021-10-01       Impact factor: 5.250

Review 6.  Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia.

Authors:  Anusha Sivakumar; Stephanie Cherqui
Journal:  Front Genome Ed       Date:  2022-05-17

7.  Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion.

Authors:  Xiulong Shen; Audrius Kilikevicius; Daniel O'Reilly; Thazha P Prakash; Masad J Damha; Frank Rigo; David R Corey
Journal:  Bioorg Med Chem Lett       Date:  2018-07-21       Impact factor: 2.823

Review 8.  Update on the Treatment of Ataxia: Medication and Emerging Therapies.

Authors:  Susan L Perlman
Journal:  Neurotherapeutics       Date:  2020-10-06       Impact factor: 7.620

Review 9.  CRISPR-based genome editing through the lens of DNA repair.

Authors:  Tarun S Nambiar; Lou Baudrier; Pierre Billon; Alberto Ciccia
Journal:  Mol Cell       Date:  2022-01-20       Impact factor: 17.970

10.  Defining Transcription Regulatory Elements in the Human Frataxin Gene: Implications for Gene Therapy.

Authors:  Jixue Li; Yanjie Li; Jun Wang; Trevor J Gonzalez; Aravind Asokan; Jill S Napierala; Marek Napierala
Journal:  Hum Gene Ther       Date:  2020-07-13       Impact factor: 4.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.